Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A phase III double-blind randomized clinical trial on the effects of ganoderma spore lipids
to the immunological response in patients with G.I. Cancers. The trial is randomized,
double-blind. Cancer patients are diagnosed based on pathology or cell biology. Patients are
randomized into 2 groups: both groups receive chemotherapy. Either group receives ganoderma
spore lipids or placebo capsules 600mg three times a day (TID) in addition to the
chemotherapy. Clinical evaluation includes chemotherapy drug toxicities, life quality
improvement. Blood biochemistry tests mainly include malondialdehyde (MDA), superoxide
dismutase (SOD), glutathione peroxidase (GSH-Px), adrenaline, nor-adrenaline, tumor necrosis
factor (TNF)-α, interleukin (IL)-1b, interleukin (IL)-6, cell flow cytometry on Th1, Th2,
Th17, Treg cytokines, as well as serum cortisol, estradiol (female), progesterone (female),
testosterone (male), etc.